Clinical Trial Update: Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating prevention of contrast-induced nephropathy during diagnostic coronary angiography or PCI using hydration guided by LEVDP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy
• Coronary Artery Disease
• Renal Failure

Snippet

Sponsor: Université de Sherbrooke | Conditions: Radiographic Contrast Agent Nephropathy, Renal Failure | Phase 4 | Status: UNKNOWN